Lipigon Pharmaceuticals AB (9RP) Stock Statistics & Valuation Metrics

Lipigon Pharmaceuticals AB has a market cap or net worth of €7.58M. The enterprise value is €77.21M.

Lipigon Pharmaceuticals AB has 563,655,940 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lipigon Pharmaceuticals AB’s return on equity (ROE) is -3.26 and return on invested capital (ROIC) is -338.69%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Lipigon Pharmaceuticals AB had revenue of 10.29M and earned -25.26M in profits. Earnings per share was -0.18.

In the last 12 months, operating cash flow was -25.92M and capital expenditures -235.00K, giving a free cash flow of -26.15M billion.

Lipigon Pharmaceuticals AB pays an annual dividend of ―, resulting in a dividend yield of ―

Lipigon Pharmaceuticals AB upcoming earnings date is Nov 20, 2025, Before Open (Not Confirmed).

Lipigon Pharmaceuticals AB as a current ratio of 2.07, with Debt / Equity ratio of 0.00%

In the past 12 months, Lipigon Pharmaceuticals AB has paid 0.00 in taxes.

Lipigon Pharmaceuticals AB EV to EBITDA ratio is -0.17, with an EV/FCF ratio of -0.17.

Lipigon Pharmaceuticals AB has €3.76M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€3.76M billion.

Gross margin is -45.35%, with operating margin of -255.53%, and net profit margin of -245.59%.

The average price target for Lipigon Pharmaceuticals AB is ―, which is 11.43% higher than the current price. The consensus rating is ―